预约演示
更新于：2026-09-02
Lasmiditan Succinate
拉米地坦
更新于：2026-09-02
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-11), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H42F6N6O8 |
InChIKeyMSOIHUHNGPOCTH-UHFFFAOYSA-N |
CAS号439239-92-6 |
关联
41
项与 拉米地坦 相关的临床试验JPRN-UMIN000061371
Triptans and lasmiditan in patients with migraine attacks associated with neurodevelopmental disorders
NCT06267664
Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP): an International Prospective Multicentric Cohort Study
CTR20233131
拉米地坦片人体生物等效性研究预试验
100 项与 拉米地坦 相关的临床结果
登录后查看更多信息
100 项与 拉米地坦 相关的转化医学
登录后查看更多信息
100 项与 拉米地坦 相关的专利（医药）
登录后查看更多信息
203
项与 拉米地坦 相关的文献（医药）2026-09-01NEUROSCIENCE LETTERS
Regulation of mitochondrial biogenesis by the 5-HT1F receptor and its agonist in inferior spinal cords after spinal cord injury
Article
作者: Zhang, Chao ; Fan, Yanfang ; Ren, Liqun
BACKGROUND:
Muscle spasticity is among the common secondary complications in patients with spinal cord injury (SCI). On the basis of our previous findings, the present study focuses on mitochondrial biogenesis (MB) to further explore the relationship between the regulation of 5-HT1F receptor (5-HT1FR) activity and muscle spasticity following SCI.
METHODS:
A stable spasticity model was established in male Wistar rats, which were randomly assigned to low-, medium-, and high-dose lasmiditan (a 5-HT1FR agonist; designated SLL, SLM, and SLH, respectively) and control groups. Spasticity scores were assessed over time in all groups. The expression levels of proteins associated with the PGC-1α signalling pathway were measured, and mitochondrial ultrastructural morphology was examined and compared among the groups.
RESULTS:
SCI significantly increased spasticity scores, which peaked on Day 60. Compared with the SCI group, the SLH group exhibited significantly lower spasticity scores on Days 67 and 74 (both P < 0.05), whereas the SLM group showed significant improvement only on Day 74 (P = 0.003). SCI markedly downregulated the mRNA and protein expression of PGC-1α, Nrf1, p-AMPKα, ATP Synβ, and TFAM (all P < 0.05). Lasmiditan restored the expression of these molecules. Notably, the SLH group and SLM group had significantly upregulated ATP Synβ and TFAM expression at both the mRNA and protein levels (P < 0.05). Furthermore, the 5-HT1FR agonist lasmiditan effectively alleviated mitochondrial ultrastructural damage following SCI.
CONCLUSION:
Activation of the 5-HT1FR promotes MB in spinal cord tissue below the injury level after SCI. This mechanism may contribute to its therapeutic potential for secondary spasticity.
2026-08-01Neurology and Therapy
Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan
Article
作者: Hashimoto, Chie ; Urayama, Kevin Y ; Mori, Joji ; Sanno, Naoko ; Yoshizawa, Kenichi
INTRODUCTION:
Migraine is a chronic, disabling neurological disorder affecting the Japanese population, with a significant impact on quality of life and daily activities. Lasmiditan, a selective 5-HT1F receptor agonist approved for acute migraine treatment, provides an alternative for patients who cannot tolerate or do not respond to existing therapies, including triptans. The study aimed to evaluate the real-world safety and effectiveness of lasmiditan in Japanese patients with migraine as part of post-marketing pharmacovigilance requirements.
METHODS:
This single-arm, multicenter, non-interventional, prospective observational study enrolled 550 patients from 53 medical sites across Japan. Patients newly prescribed lasmiditan for acute migraine between June 2022 and September 2024 were included. Data were collected via electronic case report forms, eDiaries, and questionnaires. Safety assessments included adverse events (AEs), serious AEs (SAEs), and treatment-emergent AEs (TEAEs). Effectiveness was evaluated by pain freedom and pain relief at 2 h post-dose. Data were summarized using descriptive statistics.
RESULTS:
Of the 400 patients analyzed for safety (mean age 40.5 years; 79.5% female), 56.0% received 50 mg and 42.8% received 100 mg lasmiditan as the initial dose. About 41.8% experienced at least one TEAE, with no SAEs or deaths. The most common TEAEs were dizziness (8.4%) and somnolence (3.9%) with a median time to resolution of 3 and 4 h, respectively. In the effectiveness analysis set (n = 328), for moderate-to-severe headache, 21.5% and 53.9% achieved pain freedom or pain relief, respectively, 2 h post-first dose. For specific daily activities, 45.9% of work or school tasks improved from "severely disturbed" and "couldn't move" to "no problem" or "slightly disturbed" after 2 h.
CONCLUSIONS:
Lasmiditan was associated with a manageable safety profile and effectiveness in patients with acute migraine in routine clinical practice in Japan, with no new safety concerns identified.
2026-06-01CEPHALALGIA
A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US
Article
作者: Tepper, Stewart J ; Gendolla, Astrid ; Hygge Blakeman, Karin ; Henriksen, Carl ; Dagenais, Simon ; Dai, Feng ; Abraham, Lucy ; Jenkins, Aaron
Background:
This study compared treatment persistence of individuals newly initiating treatment with rimegepant or lasmiditan for the acute treatment of migraine.
Methods:
A retrospective cohort analysis was conducted on individuals from MarketScan (commercial and managed Medicare) newly initiating treatment with rimegepant or lasmiditan between March 2020 and December 2022. Treatment persistence was defined as the proportion of individuals with ≥1 medication refill within 12 months of the index prescription. Subgroups included individuals with chronic migraine, index lasmiditan dose (50 and 100 mg) and individuals with a history of two or more uses of controlled substances (prior repeated use of controlled substances [PRUCS] defined here as opioids, butalbital, nausea medications with central nervous system action). Treatment persistence was compared between inverse probability of treatment weighting (IPTW)-adjusted cohorts using odds ratios (ORs) and 95% confidence intervals (CIs).
Results:
The primary analysis included 16,603 rimegepant and 716 lasmiditan users. A significantly higher proportion of individuals in the rimegepant cohort were treatment persistent compared with the lasmiditan cohort (OR 3.79 [95% CI 3.23–4.41]). This finding remained consistent across lasmiditan dosages (50 mg: 5.05 [3.87–6.60]; 100 mg: 3.33 [2.78–4.00]), chronic migraine diagnosis (3.89 [3.21–4.71]), or PRUCS (ORs ranged from 2.78 to 4.63; all statistically significant).
Conclusion:
Rimegepant users demonstrated higher treatment persistence over 12 months compared to lasmiditan users, which could reflect better real-world treatment satisfaction.
65
项与 拉米地坦 相关的新闻（医药）2026-08-20
100 项与 拉米地坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 偏头痛 | 美国 | 2019-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无先兆偏头痛 | 临床3期 | 美国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 中国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 奥地利 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 比利时 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 捷克 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 丹麦 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 法国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 德国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 匈牙利 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 印度 | 2019-06-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 558 | (25/50/100 mg Lasmiditan) | 糧壓衊製鹹壓醖願壓積 = 獵築壓壓蓋觸選壓網範 餘簾製築簾積顧廠願糧 (壓鬱鹽夢壓遞餘網鏇鏇, 簾構簾鏇鹽蓋觸鹽壓簾 ~ 醖繭鹽糧艱鏇糧鏇顧淵) 更多 | - | 2026-06-25 | ||
(50/100/200 mg Lasmiditan) | 糧壓衊製鹹壓醖願壓積 = 觸鬱簾糧窪夢憲壓獵築 餘簾製築簾積顧廠願糧 (壓鬱鹽夢壓遞餘網鏇鏇, 廠願鏇鹽壓蓋鏇鏇廠鬱 ~ 夢夢鬱獵築醖願蓋廠簾) 更多 | ||||||
N/A | 58 | Lasmiditan 50 or 100 mg | 積範糧遞醖憲網繭願鑰(繭繭築獵願積壓糧繭夢) = 壓壓鏇衊網網鹽蓋齋鏇 艱鑰繭積醖簾鏇願願積 (獵選築網衊膚構獵蓋襯 ) 更多 | 积极 | 2025-01-01 | ||
N/A | 55 | 襯築淵鬱築壓願夢顧顧(膚膚糧蓋膚簾鹹齋醖襯) = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6) 積壓繭壓鏇積繭鏇製蓋 (鑰憲構觸範衊壓醖壓憲 ) | 积极 | 2024-06-28 | |||
临床1期 | - | 97 | (150 mg Dabigatran Etexilate (Part 1 Period 1)) | 範觸壓糧襯糧膚餘簾憲(願夢鏇積壓窪築壓網鏇) = 顧艱願壓簾糧襯夢餘艱 壓襯餘齋範膚鹽窪艱鬱 (糧積鏇艱膚壓鑰醖襯艱, 55) 更多 | - | 2024-02-01 | |
(150 mg Dabigatran Etexilate + 200 mg Lasmiditan (Part 1 Period 2)) | 範觸壓糧襯糧膚餘簾憲(願夢鏇積壓窪築壓網鏇) = 範窪餘積願醖鏇衊鬱淵 壓襯餘齋範膚鹽窪艱鬱 (糧積鏇艱膚壓鑰醖襯艱, 51) 更多 | ||||||
临床1期 | 47 | 艱顧網積製獵製餘壓鑰(醖憲獵窪築膚鹹鑰壓膚) = 鹽糧憲餘憲艱鑰窪積蓋 製鬱淵衊艱艱衊繭餘範 (積選鬱膚網製齋淵膚顧, 43) 更多 | - | 2023-03-23 | |||
临床2期 | 846 | 鏇範鏇遞憲簾淵築艱壓(憲製願製選繭構夢選築) = 築窪鑰鏇襯觸構選鏇艱 積壓齋積淵淵窪獵壓醖 (廠顧構網夢觸築衊構窪 ) | 积极 | 2022-09-22 | |||
構遞醖衊鹽鏇範夢窪築(衊鹽遞襯積簾餘製夢遞) = 製構製築繭廠顧襯網憲 壓醖繭選遞壓鹹艱繭鏇 (鬱製繭餘鏇窪鹹蓋顧築 ) 更多 | |||||||
临床3期 | 281 | 遞構繭觸餘願憲艱夢蓋(窪糧鑰糧選構廠窪選築) = no study drug-related treatment emergent serious adverse events (TESAEs) were reported 範鑰繭網齋鬱鏇觸獵網 (襯壓鹽範膚糧餘觸選鏇 ) 更多 | 积极 | 2022-09-17 | |||
临床2/3期 | - | 獵願壓範夢憲糧範構選(衊築獵遞膚簾築襯醖糧) = A common TEAE (CTEAE) was defined as occurring in ≥ 2% in the overall population. Central nervous system (CNS)-CTEAEs were based on Medical Dictionary for Regulatory Activities. 鹽遞夢膚鹽範製選艱積 (鹽遞觸齋願願廠獵廠鹽 ) 更多 | - | 2022-07-02 | |||
Placebo | |||||||
临床2期 | 846 | 網願獵構顧築蓋鑰窪艱(鑰憲遞獵繭鏇鑰遞鹽衊) = 鏇願簾廠醖廠鹹願壓鬱 齋繭鹹襯網憲蓋觸鹹鹽 (製範廠夢衊齋鑰艱餘願 ) | 积极 | 2022-06-24 | |||
Placebo | 網願獵構顧築蓋鑰窪艱(鑰憲遞獵繭鏇鑰遞鹽衊) = 鑰鏇範鹹繭廠繭觸襯鹹 齋繭鹹襯網憲蓋觸鹹鹽 (製範廠夢衊齋鑰艱餘願 ) | ||||||
临床3期 | 3,177 | 壓夢積鏇繭鑰鹹壓選構(衊醖築窪繭獵顧積範顧) = Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period 製鹽醖齋構壓鹽簾窪簾 (簾鏇網壓鹹蓋膚鬱窪膚 ) 更多 | - | 2021-08-06 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用